Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P4BQ
|
||||
| Former ID |
DCL001112
|
||||
| Drug Name |
LY-544344
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Discontinued in Phase 3 | [1] | ||
| Therapeutic Class |
Psychiatric
|
||||
| Company |
Eli Lilly
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H16N2O5
|
||||
| Canonical SMILES |
CC(C(=O)NC1(CCC2C1C2C(=O)O)C(=O)O)N
|
||||
| InChI |
1S/C11H16N2O5/c1-4(12)8(14)13-11(10(17)18)3-2-5-6(7(5)11)9(15)16/h4-7H,2-3,12H2,1H3,(H,13,14)(H,15,16)(H,17,18)/t4-,5-,6+,7-,11-/m0/s1
|
||||
| InChIKey |
UPSXYNJDCKOCFD-DEGUGSHBSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 2 | Target Info | Agonist | [2] | |
| Metabotropic glutamate receptor3 | Target Info | Agonist | [2] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Glutamatergic synapse | |||||
| Cocaine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Cocaine addiction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Ionotropic glutamate receptor pathway | |||||
| Metabotropic glutamate receptor group II pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Metabotropic glutamate receptor group II pathway | |||||
| Reactome | G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-418594:G alpha (i) signalling events | |||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP501:GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018821) | ||||
| REF 2 | Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.